Xlife Sciences (SIX: XLS) today published its results for the first half of 2022 ending 30 June 2022. Oliver R. Baumann, CEO Xlife Sciences, comments: “In implementing our strategy of bridging preclinical research & development to healthcare markets, we have achieved relevant steps despite a challenging market environment and can look back on six successful months overall.”

A significant milestone in the first half of 2022 was the listing of Xlife Sciences’ shares on the SME trading segment “Sparks” of the SIX Swiss Exchange on 11 February 2022 and the associated transfer from the Munich Stock Exchange. The listing on the SIX Swiss Exchange was associated with the aim of increasing the visibility of the company for investors. This promise was fulfilled for the first time in May with the publication of a “Valuation Report”; the report will next be updated as per end of December 2022. In addition, after the reporting period, the first two independent research reports on Xlife Sciences were published, both with a “Buy” rating.

Another important goal in the current 2022 financial year is to expand the portfolio of projects and intensify synergy effects and cooperation between projects. In the first half of 2022, this was achieved with the newly founded biosurgery company novaxomx, a joint venture between Xlife Sciences and curasan, a leading global provider of biomaterials for bone and tissue regeneration in dental and orthopaedic surgery: novaxomx focuses on the research, development, certification, production, and commercialisation of disruptive, biosurgical therapies for use in musculoskeletal diseases and tissue regeneration. The research and development approach of novaxomx is based on the patented “exosome” technology of another Xlife Sciences project company, Lysatpharma.

As announced in April 2022, Xlife Sciences has also intensively addressed the topic of sustainability and the sustainability issues relevant to the company's stakeholders in recent months. These ESG topics were recorded in a materiality analysis and sustainability goals were derived from this to be able to continuously measure future progress. This sustainability strategy was published after the reporting period, in September 2022; annual sustainability reporting will begin next spring with the 2022 Annual Report.

Operational progress

As of the end of June 2022, Xlife Sciences had 25 project companies in total. In the first half of 2022, these made the following pleasing progress, among other things:

• Laxxon Medical has gained Evonik Venture Capital as a new investor. Evonik Venture Capital is a subsidiary of Evonik Industries AG, a German MDAX company. In addition, Laxxon and the German specialty pharmaceutical company Evonik have entered into a joint product development and cooperation agreement. Based on this agreement, Evonik plans to manufacture tablets for Laxxon.
• xprot has signed a cooperation agreement with the University Medicine of the Johannes Gutenberg University Mainz and the Thoraxklinik Heidelberg GmbH. The collaboration focuses on new and patent-protected approaches to suppress tumor growth and increase immune defense in lung cancer.
• Xsight Optics took part in this year's StartUp competition “get started 2gether”, organised by the Thuringia Research and Technology Association and the Thuringia Ministry of Economics: The company won funding for a relevant research project for safe and reliable imaging software, and was also awarded the audience prize.
• FUSE-AI has been selected as a strategic partner in the field of digitalisation by the pharmacy associations and federations of all 16 German federal states. In addition, FUSE-AI was able to submit the application for product certification of its software Prostate.Carcinoma.ai for simpler, faster and safer prostate screenings. This certification in accordance with ISO 13485 and the Medical Device Single Audit Program (MDSAP) is well advanced and forms the basis for the software's approval in the EU and the USA, among other countries.
• For several years, palleos healthcare has played a decisive role in advancing the development of novel compounds from other Xlife Sciences projects to achieve the corresponding preclinical and clinical proof of concept goals. At the same time, in the first half of 2022 the company successfully participated in the development of new products in the areas of clinical research and medical devices of large pharmaceutical companies such as Pfizer or Roche Pharma in the first half of the year.
• QUADIRA BIOSCIENCES develops and licenses novel antibody-drug conjugates (ADCs) to partner companies in the pharmaceutical industry. In the first half of 2022, QUADIRA BIOSCIENCES successfully validated the breast cancer antibody QBX101-G in an organoid model as the first product development.
• The Swiss licensing partner Baliopharm reached an important milestone in the development of the product candidate ATROSIMAB for the treatment of non-alcoholic steatohepatitis (NASH) and potentially other chronic liver diseases: The phase I clinical development study investigating the safety, tolerability as well as pharmacokinetics and pharmacodynamics of ATROSIMAB was completed with a positive result.

Financial key figures for the first half of 2022 (as of 30 June 2022):

• From the provision of services to the project companies, Xlife Sciences generated sales revenue of CHF 372.448.- in the first half of 2022 (same period of the previous year: CHF 314.612.-)
• The result (undiluted) per share amounts to CHF -1.48.- (previous year's period: CHF -0.74.-)
• Total assets amount to CHF 470.8 million (same period of the previous year: CHF 480.0 million)
• Shareholders’ equity amounts to CHF 315.6 million (previous year’s period: CHF 318.2 million)

Outlook

The war in Ukraine, the development of inflation and concerns about a recession influenced the mood on the financial markets in the first half of 2022. These developments and events have not yet had any fundamental impact on the business activities of Xlife Sciences; however, rising interest rates could change the risk classification of individual project companies as per the end 2022 financial year and could also have an impact on the weighted average cost of capital (WACC).

“The successful partnering of projects and thus the creation of added value for our shareholders is currently our main focus. We are also concentrating on the further development of the project portfolio, including synergies within the project companies, the launch of new projects and further cooperation with renowned universities”, says Oliver R. Baumann, CEO Xlife Sciences.

The complete half-year report 2022 including the financial statements as per June 30, 2022, of Xlife Sciences AG is available for download on the Company’s website at https://www.xlifesciences.ch/en/news-and-key-figures.

Financial calendar

Annual Report 2022                   April 20, 2023

AGM 2023                                 June 22, 2023

Half-Year Report 2023              September 21, 2023

Contact

Information for journalists: IRF Reputation AG, Valentin Handschin, handschin@irf-reputation.ch

Information for investors: Xlife Sciences AG, Dennis Lennartz, dennis.lennartz@xlifesciences.ch

Xlife Sciences AG, 
Talacker 35, 
8001 Zurich, 
Switzerland,
Phone +41 44 385 84 60
info@xlifesciences.ch, www.xlifesciences.ch, 
Commercial Register Zurich CHE-330.279.788 
Stock Exchange: SIX Swiss Exchange